CoChat

Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site

Open access
Janssens, Julie, De Wit, Flore, Parveen, Nagma, Debyser, Zeger · 2022 · mBio

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

A longstanding question exists on the impact of the HIV-1 integration site on viral gene expression. This unsolved question has significant implications for the search toward an HIV-1 cure, as eradication strategies set up to reactivate and eliminate HIV-1 depend on the site where the provirus is integrated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.00007-22

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Branched DNA imaging to study HIV-1 latency and reactivation. (a, b) Compound structures of CX014442 (a) and GS-9822 (b). (c) After cell fixation and permeabilization, hybridization with target-specific Z probes allows fluorescence imaging of vDNA (red, as pointed by red arrow) and vRNA (green) with confocal microscopy, allowing us to differentiate between uninfected (vDNA− vRNA−), actively infected (vDNA+ vRNA+), and latently infected cells (vDNA+ vRNA−). Nuclei are visualized with DAPI (blue). Scale bar represents 10 μm. (d) Timeline of the transduction and reactivation experiments. SupT1 cells were transduced with HIV-1 fLuc in the presence of LEDGIN (CX014442; GS-9822) or RAL. Three days posttransduction, the virus and compounds were washed away, and fLuc reporter expression was measured. Ten days posttransduction, the cells were reactivated with 10 ng/mL TNF-α. Twenty-four hours after reactivation, cells were fixed prior to bDNA staining and imaging. (e, f) SupT1 cells were transduced with single-round HIV-1 fLuc in the presence of CX014442 (e) or RAL (f). fLuc activity was measured 3 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 3), NC, nontransduced negative control.
FIG 1 Branched DNA imaging to study HIV-1 latency and reactivation. (a, b) Compound structures of CX014442 (a) and GS-9822 (b). (c) After cell fixation and permeabilization, hybridization with target-specific Z probes allows fluorescence imaging of vDNA (red, as pointed by red arrow) and vRNA (green) with confocal microscopy, allowing us to differentiate between uninfected (vDNA− vRNA−), actively infected (vDNA+ vRNA+), and latently infected cells (vDNA+ vRNA−). Nuclei are visualized with DAPI (blue). Scale bar represents 10 μm. (d) Timeline of the transduction and reactivation experiments. SupT1 cells were transduced with HIV-1 fLuc in the presence of LEDGIN (CX014442; GS-9822) or RAL. Three days posttransduction, the virus and compounds were washed away, and fLuc reporter expression was measured. Ten days posttransduction, the cells were reactivated with 10 ng/mL TNF-α. Twenty-four hours after reactivation, cells were fixed prior to bDNA staining and imaging. (e, f) SupT1 cells were transduced with single-round HIV-1 fLuc in the presence of CX014442 (e) or RAL (f). fLuc activity was measured 3 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 3), NC, nontransduced negative control.CC BY · PubMed Central
FIG 2 bDNA imaging of LEDGIN CX014442-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with 0 to 50 μM LEDGIN CX014442. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.
FIG 2 bDNA imaging of LEDGIN CX014442-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with 0 to 50 μM LEDGIN CX014442. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.CC BY · PubMed Central
FIG 3 bDNA imaging of RAL-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with 0 to 62.3 nM RAL. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.
FIG 3 bDNA imaging of RAL-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with 0 to 62.3 nM RAL. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.CC BY · PubMed Central
FIG 4 LEDGIN CX014442, but not RAL, reduces HIV-1 transcription and reactivation. (a, b) The number of vDNA spots per cell, measured with bDNA imaging 11 days posttransduction after treatment with CX014442 (a) or RAL (b) in SupT1 cells. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells imaged and analyzed per condition are shown in Table S2b and c in the supplemental material. A Kruskal-Wallis test was used to test for statistical significance compared to the control condition: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. NC, nontransduced negative control. (c, d) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 11 days posttransduction in the presence of CX014442 (c) and RAL (d). The numbers of cells imaged and analyzed per condition are shown in Table S2b and c. The median number of vRNA spots per cell is indicated with a horizontal line. A Kruskal-Wallis test was used to test for statistical significance between the unactivated and reactivated cells of each condition: *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; and ns, nonsignificant. NC, nontransduced negative control (e) Viral RNA expression per residual copy was calculated in the presence of increasing concentrations of CX014442 or RAL by dividing the number of vRNA spots by the number of vDNA spots for the unreactivated cells (top) and reactivated cells (bottom).
FIG 4 LEDGIN CX014442, but not RAL, reduces HIV-1 transcription and reactivation. (a, b) The number of vDNA spots per cell, measured with bDNA imaging 11 days posttransduction after treatment with CX014442 (a) or RAL (b) in SupT1 cells. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells imaged and analyzed per condition are shown in Table S2b and c in the supplemental material. A Kruskal-Wallis test was used to test for statistical significance compared to the control condition: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. NC, nontransduced negative control. (c, d) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 11 days posttransduction in the presence of CX014442 (c) and RAL (d). The numbers of cells imaged and analyzed per condition are shown in Table S2b and c. The median number of vRNA spots per cell is indicated with a horizontal line. A Kruskal-Wallis test was used to test for statistical significance between the unactivated and reactivated cells of each condition: *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; and ns, nonsignificant. NC, nontransduced negative control (e) Viral RNA expression per residual copy was calculated in the presence of increasing concentrations of CX014442 or RAL by dividing the number of vRNA spots by the number of vDNA spots for the unreactivated cells (top) and reactivated cells (bottom).CC BY · PubMed Central
FIG 5 bDNA imaging of GS-9822-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with increasing concentrations of GS-9822. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.
FIG 5 bDNA imaging of GS-9822-treated cells. SupT1 cells were transduced with single-round HIV-1 and reactivated 10 days posttransduction with 10 ng/mL TNF-α. Twenty-four hours after reactivation, the cells were fixed to visualize vDNA (red) and vRNA (green) with bDNA imaging in cells treated with increasing concentrations of GS-9822. Unactivated cells (top) and TNF-α-reactivated cells (bottom) are shown. For better visualization of the vDNA spots, a zoomed image of the cell highlighted by the square box is shown for each condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm.CC BY · PubMed Central
FIG 6 LEDGIN GS-9822 reduces HIV-1 transcription and reactivation at nanomolar concentrations. (a) SupT1 cells were transduced with single-round HIV-1 expressing firefly luciferase (fLuc) in the presence of GS-9822. The fLuc activity was measured 3 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 2), performed in duplicate. NC, nontransduced negative control. (b) The numbers of vDNA spots per cell, measured with bDNA imaging 11 days posttransduction, are shown in the presence of GS-9822. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells that were imaged and analyzed per condition are shown in Table S2d in the supplemental material. A Kruskal-Wallis test was used to test for statistically significant differences compared to the control condition: **, P < 0.01, and ****, P < 0.0001. NC, nontransduced negative control. (c) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 11 days posttransduction in the presence of LEDGIN GS-9822. The median number of vRNA spots per cell is indicated with a horizontal line. A Kruskal-Wallis test was used to test for statistically significant differences between the unactivated and reactivated cells of each condition: *, P < 0.05; ns, nonsignificant. NC, nontransduced negative control. The numbers of cells that were imaged and analyzed per condition are shown in Table S2d. (d) Viral RNA expression per residual copy was calculated in the presence of increasing concentrations of GS-9822 by dividing the number of vRNA spots by the number of vDNA spots for the unreactivated cells (top) and reactivated cells (bottom).
FIG 6 LEDGIN GS-9822 reduces HIV-1 transcription and reactivation at nanomolar concentrations. (a) SupT1 cells were transduced with single-round HIV-1 expressing firefly luciferase (fLuc) in the presence of GS-9822. The fLuc activity was measured 3 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 2), performed in duplicate. NC, nontransduced negative control. (b) The numbers of vDNA spots per cell, measured with bDNA imaging 11 days posttransduction, are shown in the presence of GS-9822. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells that were imaged and analyzed per condition are shown in Table S2d in the supplemental material. A Kruskal-Wallis test was used to test for statistically significant differences compared to the control condition: **, P < 0.01, and ****, P < 0.0001. NC, nontransduced negative control. (c) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 11 days posttransduction in the presence of LEDGIN GS-9822. The median number of vRNA spots per cell is indicated with a horizontal line. A Kruskal-Wallis test was used to test for statistically significant differences between the unactivated and reactivated cells of each condition: *, P < 0.05; ns, nonsignificant. NC, nontransduced negative control. The numbers of cells that were imaged and analyzed per condition are shown in Table S2d. (d) Viral RNA expression per residual copy was calculated in the presence of increasing concentrations of GS-9822 by dividing the number of vRNA spots by the number of vDNA spots for the unreactivated cells (top) and reactivated cells (bottom).CC BY · PubMed Central
FIG 7 LEDGIN CX014442 treatment in primary cells hampers HIV-1 transcription and reactivation from latency. (a) Peripheral blood mononuclear cells (PBMCs, donor 1) were transduced with single-round HIV-1 expressing firefly luciferase (fLuc) in the presence of LEDGIN CX014442. On day 4 posttransduction, half of the cells were activated with 100 nM PMA, and samples were harvested for bDNA imaging 7 days posttransduction. (b) PBMCs were transduced with single-round HIV-1 and reactivated 4 days posttransduction with 100 nM PMA. On day 7, 72 h after reactivation, the cells were fixed to visualize vDNA (red, as pointed by red arrow) and vRNA (green) with bDNA imaging. Representative images are shown for the control condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm. (c) fLuc activity was measured 4 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 3), performed in duplicate. (d) The number of vDNA spots per cell, measured with bDNA imaging 7 days posttransduction, is shown in the presence of CX014442. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells that were imaged and analyzed per condition are shown in Table S2e in the supplemental material. A Kruskal-Wallis test was used to test for statistically significant differences compared to the control condition: ***, P < 0.001. (e) The average number of vDNA spots per cell is shown as mean ± SEM. (f) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 7 days posttransduction in the presence of CX014442. The numbers of cells that were imaged and analyzed per condition are shown in Table S2e.
FIG 7 LEDGIN CX014442 treatment in primary cells hampers HIV-1 transcription and reactivation from latency. (a) Peripheral blood mononuclear cells (PBMCs, donor 1) were transduced with single-round HIV-1 expressing firefly luciferase (fLuc) in the presence of LEDGIN CX014442. On day 4 posttransduction, half of the cells were activated with 100 nM PMA, and samples were harvested for bDNA imaging 7 days posttransduction. (b) PBMCs were transduced with single-round HIV-1 and reactivated 4 days posttransduction with 100 nM PMA. On day 7, 72 h after reactivation, the cells were fixed to visualize vDNA (red, as pointed by red arrow) and vRNA (green) with bDNA imaging. Representative images are shown for the control condition. Nuclei are stained with DAPI (blue), and scale bars represent 10 μm. (c) fLuc activity was measured 4 days posttransduction and normalized for the total protein content. The normalized fLuc activity is shown as mean ± standard deviation from one representative experiment (n = 3), performed in duplicate. (d) The number of vDNA spots per cell, measured with bDNA imaging 7 days posttransduction, is shown in the presence of CX014442. Pooled data from the unactivated and reactivated cells are shown. The numbers of cells that were imaged and analyzed per condition are shown in Table S2e in the supplemental material. A Kruskal-Wallis test was used to test for statistically significant differences compared to the control condition: ***, P < 0.001. (e) The average number of vDNA spots per cell is shown as mean ± SEM. (f) The numbers of vRNA spots per infected cell are shown for the unactivated and reactivated cells, measured with bDNA imaging 7 days posttransduction in the presence of CX014442. The numbers of cells that were imaged and analyzed per condition are shown in Table S2e.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 28

Metadata

Authors
Janssens, J., De Wit, F., Parveen, N., & Debyser, Z.
Affiliations
  • KU Leuven (BE)
  • Molecular Virology and Gene Therapy, KU Leuven, Leuven, Belgium
  • Indian Institute of Technology Kanpur (IN)
Corresponding author
Debyser, Zeger
Venue
mBio
Published
2022-08-30
Volume
13
Issue
4
Pages
e0000722-e0000722
ISSN
2150-7511 (ISSN-L)
OpenAlex
W4282980960
Cited by
28
References
67
Citations by year
2026: 6 · 2025: 6 · 2024: 11 · 2023: 4 · 2022: 1
FWCI
1.79
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fonds Wetenschappelijk Onderzoek (G0A5316N, SBO-Saphir)
  • KU Leuven research council (C14/17/095-3M170311)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
HIV-1 provirus, integration sites, HIV-1 transcription, viral reactivation, LEDGF/p75, HIV-1 integrase, 3D genome organization, HIV-1 cure, chromatin targeting
MeSH terms
Chromatin, HIV Seropositivity, Humans, Proviruses, Virus Replication, HIV-1, Virus Integration, HIV Integrase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.